Search

Your search keyword '"Lindsay C. R."' showing total 31 results

Search Constraints

Start Over You searched for: Author "Lindsay C. R." Remove constraint Author: "Lindsay C. R."
31 results on '"Lindsay C. R."'

Search Results

2. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

3. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

5. The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer

6. Body composition and lung cancer-associated cachexia in TRACERx

7. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

8. Genomic–transcriptomic evolution in lung cancer and metastasis

9. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

10. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

11. The evolution of lung cancer and impact of subclonal selection in TRACERx

16. Petrogenesis and Implications of Calc-Alkaline Cryptic Hybrid Magmas from Washburn Volcano, Absaroka Volcanic Province, USA

18. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.

21. Phase I dose-escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors.

24. Petrogenesis and Implications of Calc-Alkaline Cryptic Hybrid Magmas from Washburn Volcano, Absaroka Volcanic Province, USA

26. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.

27. Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts.

28. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.

29. KRAS: Reasons for optimism in lung cancer.

30. CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies.

31. Thymic malignancies: Moving forward with new systemic treatments.

Catalog

Books, media, physical & digital resources